Literature DB >> 6121050

gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor.

K G Lloyd, S Arbilla, K Beaumont, M Briley, G De Montis, B Scatton, S Z Langer, G Bartholini.   

Abstract

Progabide and its immediate metabolite SL 75102 displace [3H]gamma-aminobutyric acid (GABA), [3H]muscimol and [3H]isoguvacine from their binding sites to membranes prepared from rat brain or human cerebellum and increase (SL 75102) [3H]flunitrazepam binding to rat cerebral cortex membranes. In contrast, these compounds have very weak or no effects on alpha or beta noradrenergic, histamine, muscarinic cholinergic or glycine receptors or on the [3H]imipramine or [3H]kainate binding sites. Neither progabide nor SL 75102 inhibit GABA synthesis, metabolism or uptake. Also, the uptake of norepinephrine, serotonin and dopamine into synaptosomes of cerebral regions is not affected by progabide. [3H]GABA release from substantia nigra slices is decreased by SL 75102 and progabide, in agreement with the hypothesis of a GABAergic autoreceptor controlling GABA release from its nerve terminals. These data suggest a specific agonist action of progabide and SL 75102 on GABA receptors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121050

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Acid metabolite of progabide pharmacokinetics following single administration in the rabbit with special references to HPLC and (3H) muscimol radioreceptor assay.

Authors:  C Brunet; M Luyckx; M Lhermitte
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

2.  Differential effects of chronic antidepressants in behavioural tests of beta-adrenergic and GABAB receptor function.

Authors:  D J McManus; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes. 1983.

Authors:  N G Bowery; D R Hill; A L Hudson
Journal:  Br J Pharmacol       Date:  1997-02       Impact factor: 8.739

4.  An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site.

Authors:  J P Chambon; P Feltz; M Heaulme; S Restle; R Schlichter; K Biziere; C G Wermuth
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

5.  GABA mimetics increase extracellular DOPAC (as measured by in vivo voltammetry) in the rat locus coeruleus.

Authors:  B Scatton; A Serrano
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

6.  The comparative effects of benzodiazepines, progabide and PK 9084 on acquisition of passive avoidance in mice.

Authors:  C L Broekkamp; M Le Pichon; K G Lloyd
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys.

Authors:  Lance R McMahon; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2004-10-14       Impact factor: 4.530

8.  Effects of the putative antagonists phaclofen and delta-aminovaleric acid on GABAB receptor biochemistry.

Authors:  T N Robinson; A J Cross; A R Green; J M Toczek; B R Boar
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

Review 9.  GABAergic mechanisms in the pathogenesis and treatment of epilepsy.

Authors:  B S Meldrum
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

10.  Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes.

Authors:  N G Bowery; D R Hill; A L Hudson
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.